Interim findings from an ongoing Phase II clinical trial indicate that the investigational drug continues to demonstrate a stable and predictable safety profile. Across the enrolled participants, adverse events remained within anticipated ranges and aligned with preclinical and early-phase trial data.

Researchers emphasize that consistent safety outcomes across dosing cohorts strengthen confidence in the study’s design and dosing strategy. Ongoing monitoring and data collection will further inform optimal dosing parameters and long-term safety considerations as the trial progresses.